Validation of the semiquantitative static SUVR method for 18F-AV45 PET by pharmacokinetic modeling with an arterial input function

Journal of Nuclear Medicine

Volumn 58, Issue 9, 2017, Pages 1483-1489

  Ottoy, Julie ^a   Verhaeghe, Jeroen ^a   Niemantsverdriet, Ellis ^b   Wyffels, Leonie ^c   Somers, Charisse ^b   De Roeck, Ellen ^b,d   Struyfs, Hanne ^b   Soetewey, Femke ^b   Deleye, Steven ^a   Van Den Bossche, Tobi ^a,b,c,e   Van Mossevelde, Sara ^a,b,c,e   Ceyssens, Sarah ^c   Versijpt, Jan ^f   Stroobants, Sigrid ^c   Engelborghs, Sebastiaan ^b,e   Staelens, Steven ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e Hospital Network Antwerp (ZNA) Hoge Beuken and Middelheim   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

18F AV45; Alzheimer's disease; Amyloid; Cerebral perfusion; Kinetic modeling

Indexed keywords

AV 45; FLORBETAPIR F 18; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGED; ANALYTICAL PARAMETERS; ARTICLE; BRAIN; BRAIN BLOOD FLOW; CENTRUM SEMIOVALE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG UPTAKE; FEMALE; GRAY MATTER; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PONS; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUV RATIO; VALIDATION STUDY; WHITE MATTER; BIOLOGICAL MODEL; BRAIN CIRCULATION; DIAGNOSTIC IMAGING; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

AGED; ANILINE COMPOUNDS; BIOLOGICAL TRANSPORT; BRAIN; CEREBROVASCULAR CIRCULATION; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 85028176932     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.184481     Document Type: Article

References (28)

1. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science. 1992;256: 184-185.
2. Pike KE, Savage G, Villemagne VL, et al. b-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain. 2007;130: 2837-2844.
3. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces amyloidbeta plaques in Alzheimer's disease. Nature. 2016;537: 50-56.
4. Timmers M, Van Broeck B, Ramael S, et al. Profiling the dynamics of CSF and plasma Abeta reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement Transl Res Clin Interv. 2016;2: 202-212.
5. Forlenza OV, Radanovic M, Talib LL, et al. Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimers Dement (Amst). 2015;1: 455-463.
6. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011;10: 667-670.
7. Vandenberghe R, Adamczuk K, Van Laere K. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. Curr Opin Neurol. 2013; 26: 646-655.
8. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55: 306-319.
9. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25: 1528-1547.
10. 18F-AV-45: A PET agent for Ab plaques in the brain. J Nucl Med. 2009;50: 1887-1894.
11. Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement. 2015;11: 757-771.
12. 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56: 567-574.
13. 18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108: 450-459.
14. Chen K, Roontiva A, Thiyyagura P, et al. Improved power for characterizing longitudinal amyloid-b PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56: 560-566.
15. 18F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther. 2016;8: 2-12.
16. van Berckel BNM, Ossenkoppele R, Tolboom N, et al. Longitudinal amyloid imaging using 11C-PiB: Methodologic considerations. J Nucl Med. 2013;54: 1570-1576.
17. Cselényi Z, Farde L. Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. J Cereb Blood Flow Metab. 2015;35: 1485-1493.
18. Mazza M, Marano G, Traversi G, Bria P, Mazza S. Primary cerebral blood flow deficiency and Alzheimer's disease: Shadows and lights. J Alzheimers Dis. 2011; 23: 375-389.
19. Austin BP, Nair VA, Meier TB, et al. Effects of hypoperfusion in Alzheimer's disease. J Alzheimers Dis. 2011;26(suppl 3): 123-133.
20. Niemantsverdriet E, Feyen B, Le Bastard N, et al. Overdiagnosing vascular dementia using structural brain imaging for dementia work-up. J Alzheimers Dis. 2015;45: 1039-1043.
21. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7: 263-269.
22. 18FAV45 (Florbetapir F 18) for imaging b-amyloid plaques in human brain. Appl Radiat Isot. 2010;68: 2293-2297.
23. 18F-AV-45 (florbetapir F-18). J Nucl Med. 2010;51: 913-920.
24. 18F]FDG kinetics for heart and brain studies with PET. IEEE Trans Biomed Eng. 1998;45: 1429-1448.
25. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22: 1271-1281.
26. 18F-florbetaben binding to b-amyloid deposits in human brains. J Nucl Med. 2013;54: 723-731.
27. Chen YJ, Rosario BL, Mowrey W, et al. Relative 11C-PiB delivery as a proxy of relative CBF: Quantitative evaluation using single-session 15O-water and 11C-PiB PET. J Nucl Med. 2015;56: 1199-1205.
28. 18F-florbetaben study. BMC Neurol. 2015;15: 243.